Trinity Biotech PLC (TRIB)
1.802
+0.12
(+7.27%)
USD |
NASDAQ |
May 03, 16:00
1.76
-0.04
(-2.34%)
Pre-Market: 20:00
Trinity Biotech Revenue (Quarterly): 13.43M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.43M |
| September 30, 2023 | 14.68M |
| June 30, 2023 | 13.90M |
| March 31, 2023 | 14.83M |
| December 31, 2022 | 15.73M |
| September 30, 2022 | 15.70M |
| June 30, 2022 | 15.42M |
| March 31, 2022 | 15.68M |
| December 31, 2021 | 7.708M |
| September 30, 2021 | 22.00M |
| June 30, 2021 | 25.84M |
| March 31, 2021 | 25.59M |
| December 31, 2020 | 32.76M |
| September 30, 2020 | 32.01M |
| June 30, 2020 | 16.02M |
| March 31, 2020 | 21.18M |
| December 31, 2019 | 21.32M |
| September 30, 2019 | 24.59M |
| June 30, 2019 | 22.50M |
| March 31, 2019 | 22.03M |
| December 31, 2018 | 24.52M |
| September 30, 2018 | 23.71M |
| June 30, 2018 | 25.00M |
| March 31, 2018 | 23.80M |
| December 31, 2017 | 24.55M |
| Date | Value |
|---|---|
| September 30, 2017 | 25.60M |
| June 30, 2017 | 25.45M |
| March 31, 2017 | 23.54M |
| December 31, 2016 | 23.68M |
| September 30, 2016 | 26.13M |
| June 30, 2016 | 26.29M |
| March 31, 2016 | 23.52M |
| December 31, 2015 | 24.94M |
| September 30, 2015 | 25.76M |
| June 30, 2015 | 24.26M |
| March 31, 2015 | 25.24M |
| December 31, 2014 | 26.68M |
| September 30, 2014 | 27.16M |
| June 30, 2014 | 26.00M |
| March 31, 2014 | 25.02M |
| December 31, 2013 | 25.46M |
| September 30, 2013 | 24.12M |
| June 30, 2013 | 21.31M |
| March 31, 2013 | 20.33M |
| December 31, 2012 | 20.82M |
| September 30, 2012 | 20.85M |
| June 30, 2012 | 20.81M |
| March 31, 2012 | 20.03M |
| December 31, 2011 | 20.01M |
| September 30, 2011 | 19.83M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.708M
Minimum
Dec 2021
32.76M
Maximum
Dec 2020
19.52M
Average
16.02M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| Avadel Pharmaceuticals PLC | 19.45M |
| Amarin Corp PLC | 74.71M |
| DBV Technologies SA | -- |
| Adaptimmune Therapeutics PLC | 0.231M |
| Akari Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.501M |
| Total Expenses (Quarterly) | 16.92M |
| EPS Diluted (Quarterly) | -2.872 |
| Enterprise Value | 68.23M |
| Gross Profit Margin (Quarterly) | 34.01% |
| Profit Margin (Quarterly) | -40.97% |
| Earnings Yield | -293.4% |
| Normalized Earnings Yield | -308.22 |